Mydecine Innovations Group Inc. (MYCOF)
MYCOF Stock Price Chart
Explore Mydecine Innovations Group Inc. interactive price chart. Choose custom timeframes to analyze MYCOF price movements and trends.
MYCOF Company Profile
Discover essential business fundamentals and corporate details for Mydecine Innovations Group Inc. (MYCOF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
8 Jan 2021
Employees
3.00
Website
https://www.mydecine.comCEO
David Joshua Bartch
Description
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
MYCOF Financial Timeline
Browse a chronological timeline of Mydecine Innovations Group Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Nov 2025
Earnings released on 22 Jul 2025
Earnings released on 9 Jul 2025
EPS came in at -$0.00 .
Earnings released on 18 Nov 2024
EPS came in at -$0.02 .
Earnings released on 16 Aug 2024
EPS came in at -$0.03 .
Earnings released on 28 Jun 2024
EPS came in at -$0.01 .
Earnings released on 29 Mar 2024
EPS came in at -$0.14 .
Earnings released on 15 Nov 2023
EPS came in at -$0.29 .
Earnings released on 15 Aug 2023
EPS came in at -$0.10 .
Earnings released on 16 May 2023
EPS came in at -$0.40 surpassing the estimated -$0.74 by +45.60%.
Earnings released on 29 Mar 2023
EPS came in at $0.02 .
Earnings released on 14 Nov 2022
EPS came in at -$0.29 surpassing the estimated -$0.72 by +59.33%.
Earnings released on 15 Aug 2022
EPS came in at -$0.35 surpassing the estimated -$1.00 by +65.00%.
Earnings released on 16 May 2022
EPS came in at -$1.20 falling short of the estimated -$1.00 by -20.00%.
Stock split effective on 21 Apr 2022
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2022
EPS came in at -$75.00 falling short of the estimated -$1.00 by -7.40K%, while revenue for the quarter reached $5.88K .
Earnings released on 15 Nov 2021
EPS came in at -$1.00 falling short of the estimated -$0.50 by -100.00%, while revenue for the quarter reached $57.58 , missing expectations by -99.94%.
Earnings released on 16 Aug 2021
EPS came in at -$1.00 matching the estimated -$1.00, while revenue for the quarter reached $4.19K .
Earnings released on 17 May 2021
EPS came in at -$0.99 , while revenue for the quarter reached $12.74K .
Earnings released on 30 Apr 2021
EPS came in at -$24.83 , while revenue for the quarter reached $11.83K .
Earnings released on 30 Sept 2020
EPS came in at -$2.81 , while revenue for the quarter reached $12.89K .
MYCOF Stock Performance
Access detailed MYCOF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.